Sanofi Starts the Year Strong -- Market Talk

Dow Jones

2025/04/24

1005 GMT - Sanofi surprised with a sales beat of its skin and asthma drug Dupixent and a gross margin improvement given cost discipline, Stifel analysts say in a note. In addition, the French drugmaker's insulin portfolio is still benefiting from less competition in the U.S., where Danish obesity drug maker Novo Nordisk is prioritising its GLP-1 portfolio, they add. "[This was] a very good start to the year, offering upside to guidance, although Sanofi keeps it unchanged for the time being, which makes sense given uncertainties in the sector," they say. Shares fall 1% to 92.73 euros. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

April 24, 2025 06:06 ET (10:06 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2529605801"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2529605801\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2529605801?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-24 18:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529605801","market":"hk","top_or_hot":-1,"title":"Sanofi Starts the Year Strong -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1005 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> surprised with a sales beat of its skin and asthma drug Dupixent and a gross margin improvement given cost discipline, Stifel analysts say in a note. In addition, the French drugmaker's insulin portfolio is still benefiting from less competition in the U.S., where Danish obesity drug maker Novo Nordisk is prioritising its GLP-1 portfolio, they add. \"[This was] a very good start to the year, offering upside to guidance, although Sanofi keeps it unchanged for the time being, which makes sense given uncertainties in the sector,\" they say. Shares fall 1% to 92.73 euros. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2025 06:06 ET (10:06 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Starts the Year Strong -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Starts the Year Strong -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-24 18:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1005 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> surprised with a sales beat of its skin and asthma drug Dupixent and a gross margin improvement given cost discipline, Stifel analysts say in a note. In addition, the French drugmaker's insulin portfolio is still benefiting from less competition in the U.S., where Danish obesity drug maker Novo Nordisk is prioritising its GLP-1 portfolio, they add. \"[This was] a very good start to the year, offering upside to guidance, although Sanofi keeps it unchanged for the time being, which makes sense given uncertainties in the sector,\" they say. Shares fall 1% to 92.73 euros. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2025 06:06 ET (10:06 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNYNF","symbol_name":"Sanofi","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2529605801","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529605801","pubTimestamp":1745489160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1005 GMT - Sanofi surprised with a sales beat of its skin and asthma drug Dupixent and a gross margin improvement given cost discipline, Stifel analysts say in a note. In addition, the French drugmaker's insulin portfolio is still benefiting from less competition in the U.S., where Danish obesity drug maker Novo Nordisk is prioritising its GLP-1 portfolio, they add. \"[This was] a very good start to the year, offering upside to guidance, although Sanofi keeps it unchanged for the time being, which makes sense given uncertainties in the sector,\" they say. Shares fall 1% to 92.73 euros. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNYNF":"Sanofi","BK4007":"制药","SNY":"赛诺菲安万特","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC"},"translate_title":"赛诺菲今年开局强劲——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1,"SNY":0.9},"content_text":"1005 GMT - Sanofi surprised with a sales beat of its skin and asthma drug Dupixent and a gross margin improvement given cost discipline, Stifel analysts say in a note. In addition, the French drugmaker's insulin portfolio is still benefiting from less competition in the U.S., where Danish obesity drug maker Novo Nordisk is prioritising its GLP-1 portfolio, they add. \"[This was] a very good start to the year, offering upside to guidance, although Sanofi keeps it unchanged for the time being, which makes sense given uncertainties in the sector,\" they say. Shares fall 1% to 92.73 euros. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 24, 2025 06:06 ET (10:06 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}